ClinicalTrials.gg
RecruitingNCT06014190Updated Aug 29, 2024

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

A Phase 2 interventional study of HS-20089 in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by Hansoh BioMedical R&D Company. Recruiting at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 392 studies in Ovarian Neoplasms with a site in China — 198 open to participants now, 231 under way, 35 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
29th of 319
460 · median 83
Started
2023
with 34 others
Phase 2
106 of 392
53 open now
Primary completion
2025-12
later than 57 of 230 live
Registered
216th of 392
by date

Among the 392 studies in Ovarian Neoplasms with a site in China, this one is the 29th largest by planned enrollment of the 319 interventional ones that give a count, is one of 35 that started in 2023, is one of 106 in phase 2, reaches primary completion later than 57 of the 230 other live ones, and was the 216th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

198 of the 392 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

193 more — sign in →

All 198 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 392 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6.

This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20089 as monotherapy in patients with recurrent or metastatic ovarian cancer and endometrial cancer.

Read the detailed description

This is a phase 2, open-label, multi-center study composed of two parts: phase 2a and phase 2b.

Phase 2a: This part of study will be conducted in the following four cohorts: Cohort 1: Patients with platinum-resistant ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Cohort 2: Patients with recurrent or metastatic endometrial cancer who have progressed on or are intolerant to at least one line of standard platinum-based chemotherapy. Cohort 3: Patients with platinum-sensitive ovarian cancer, fallopian tube cancer or primary peritoneal cancer who have progressed on or are intolerant to at least two lines of standard platinum-based chemotherapy. Cohort 4: Patients with other advanced solid tumors who have progressed on or are intolerant to established standard therapies. Patients in cohort 1 will be randomly assigned 1:1 to receive HS-20089 at 4.8 mg/kg or 5.8 mg/kg and patients in the other three cohorts will receive HS-20089 at 5.8 mg/kg.

Phase 2b: This part of study will be conducted in the following two cohorts: Cohort 1: Patients with platinum-resistant ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Cohort 2: Patients with recurrent or metastatic endometrial cancer who have progressed on or are intolerant to at least one line of standard platinum-based chemotherapy. The cohorts may be adjusted based on the observed clinical results, translational medicine data and research progress in the field. All patients will receive HS-20089 at the recommended dose (RD) determined by accumulated research data.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
  • Endometrial Cancer

Keywords

  • HS-20089
  • B7-H4
  • Antibody-drug Conjugate
  • Ovarian Cancer
  • Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 18 years or older (≥18 years).
  2. Patients diagnosed with recurrent or ovarian cancer, endometrial cancer or other solid tumors.
  3. Subjects have at least one target lesion as assessed per the 1.1. Patients with only brain and/or bone lesions as target lesions are ineligible.
  4. Tumor tissue from a newly obtained (FFPE tumor tissue blocks or slides are acceptable) is required. If the newly obtained biopsy is not feasible, newly obtained FFPE slides cut from archival tumor tissue blocks within 2 years prior to the first dose of study drug are acceptable.
  5. Performance Status (ECOG PS) score of 0 to 1 and no deterioration within 2 weeks before the first dose.
  6. Have a of at least 12 weeks.
  7. Female subjects of are willing to take appropriate measures and should not breastfeed from signing the until 6 months after the last dose; male subjects must agree to use barrier contraception (i.e. condoms) from signing the informed consent to 6 months after the last dose.
  8. Female subjects must have a negative pregnancy test within 7 days prior to the first dose (for subjects with tumor related abnormal elevation of human chorionic gonadotropin [HCG], an ultrasound of uterus and appendages should be performed within 7 days prior to the first dose to rule out pregnancy), or demonstrate no risk for pregnancy.
  9. Subject must be voluntarily enrolled in this clinical trial, be able to understand the study procedures and to sign written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Have received or is currently receiving the following treatment:

    1. B7-H4-targeted therapies.
    2. Have received any of cytotoxic chemotherapy drugs, drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs (including endocrine therapy, molecular targeted therapy, biotherapy, etc.) within 14 days prior to the first dose of study drug; or need to continue these drugs during the study.
    3. Have received macromolecular antitumor drugs (including immunotherapy, such as monoclonal antibodies and bispecific antibodies) within 28 days prior to the first dose of study drug.
    4. Have received locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study treatment.
    5. Major surgery (such as craniotomy, thoracotomy or laparotomy, etc.) within 4 weeks prior to the first dose of study treatment.
    6. Use of strong inhibitors or inducers of , CYP2D6, P-gp, or BCRP, or sensitive substrates of CYP3A4, CYP2D6, P-gp, or BCRP with narrow therapeutic window within 7 days prior to the first dose of study drug; or in need of continuing treatment with these drugs during the study.
    7. Current use of drugs known to prolong the or potentially cause torsades de pointes; or need to continue these medications during the study.
  2. Presence of Grade ≥ 2 toxicities as per (CTCAE version 5.0) due to prior anti-tumor therapy (except alopecia and residual neurotoxicity).
  3. Presence of pleural/abdominal effusion requiring clinical intervention.
  4. Known history of prior .
  5. Evidence of , unless meeting all of the following criteria:

    1. Asymptomatic; medically stable for at least four weeks prior to the first dose;
    2. No treatment required for at least two weeks prior to the first dose;
    3. No stereotactic radiation therapy, whole brain radiotherapy, and/or neurosurgical resection within 4 weeks prior to the first dose;
    4. No history of intracranial or spinal hemorrhage;
    5. Have at least one target lesion other than CNS lesion according to v1.1;
  6. Inadequate bone marrow reserve or hepatic/renal functions.
  7. Cardiological examination abnormality.
  8. Severe, uncontrolled or active cardiovascular disorders.
  9. Serious or poorly controlled diabetes.
  10. Serious or poorly controlled hypertension.
  11. bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose of study treatment.
  12. Serious arteriovenous thromboembolic events within 3 months prior to the first dose of study treatment.
  13. Serious infections within 4 weeks prior to the first dose.
  14. Have received systemic glucocorticoid therapy for more than 30 days within 30 days prior to the first dose study treatment, or require chronic (≥ 30 days) use of systemic glucocorticoids during the study, or have other acquired, congenital immunodeficiency disorders, or a history of organ transplantation.
  15. Presence of active infectious diseases such as , , tuberculosis, syphilis, or infection, etc.
  16. Current hepatic encephalopathy, hepatorenal syndrome, or Class B or more severe cirrhosis.
  17. Any moderate or severe lung diseases that may interfere with the detection and treatment of drug-related pulmonary toxicity or may seriously affect respiratory function.
  18. History of severe neurological or psychiatric disorder.
  19. Pregnant or breast-feeding women or women who intend to become pregnant during the study.
  20. Attenuated within 4 weeks prior to the first dose.
  21. Allergies or reactions within 4 weeks prior to the first dose. History of severe allergies (e.g., anaphylactic shock), or severe infusion-related reactions. Allergy or hypersensitivity to any component of HS-20089.
  22. Subjects unlikely to comply with study procedures, restrictions and requirement as determined by the investigator.
  23. Subjects with any condition that jeopardizes the safety of the patient or interferes with the assessment of the study, as judged by the investigator.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
460 participants (estimated)

Study arms

  • Experimental
    Cohort 1 at 4.8 mg/kg of HS-20089 (Phase 2a)

    Patients in cohort 1 of phase 2a will be randomly assigned to receive HS-20089 at 4.8 mg/kg or 5.8 mg/kg.

    Drug: HS-20089

  • Experimental
    Cohort 1 at 5.8 mg/kg of HS-20089 (Phase 2a)

    Patients in cohort 1 of phase 2a will be randomly assigned to receive HS-20089 at 4.8 mg/kg or 5.8 mg/kg.

    Drug: HS-20089

  • Experimental
    Cohort 2 at 5.8 mg/kg of HS-20089 (Phase 2a)

    Patients in cohort 2 of phase 2a will receive HS-20089 at 5.8 mg/kg.

    Drug: HS-20089

  • Experimental
    Cohort 3 at 5.8 mg/kg of HS-20089 (Phase 2a)

    Patients in cohort 3 of phase 2a will receive HS-20089 at 5.8 mg/kg.

    Drug: HS-20089

  • Experimental
    Cohort 4 at 5.8 mg/kg of HS-20089 (Phase 2a)

    Patients in cohort 4 of phase 2a will receive HS-20089 at 5.8 mg/kg.

    Drug: HS-20089

  • Experimental
    Recommended dose of HS-20089 (Phase 2b)

    Patients of phase 2b will receive HS-20089 at recommended dose.

    Drug: HS-20089

Interventions

  • All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    ORR is defined as the percentage of participants who achieved a best overall response (BOR) of confirmed complete response (CR) or partial response (PR), assessed by investigators based on RECIST 1.1.

    Time frame: From the first dose up to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

Secondary outcomes

  1. ORR assessed by independent review committee (IRC) according to RECIST 1.1

    ORR is defined as the percentage of participants who achieved a BOR of confirmed CR or PR, assessed by IRC based on RECIST 1.1.

    Time frame: From the first dose to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

  2. Duration of response (DoR) assessed by investigators and IRC according to RECIST 1.1

    DoR is defined as the period from the first occurrence of CR or PR to progressive disease (PD) or death of any cause. If no PD or death after CR/PR, the cut-off date of progression-free survival (PFS) will be used.

    Time frame: From the first dose to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

  3. Disease control rate (DCR) assessed by investigators and IRC according to RECIST 1.1

    DCR is defined as the percentage of participants with BOR of confirmed CR, PR and stable disease (SD).

    Time frame: From the first dose to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

  4. Progression-free survival (PFS) assessed by investigators and IRC according to RECIST 1.1

    PFS is defined as the time from first dose or randomization (if any) to PD or death of any cause.

    Time frame: From the first dose or randomization to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

  5. Overall survival (OS)

    OS is defined as the time from the first dose or randomization (if any) to death of any cause.

    Time frame: From the first dose or randomization to death or withdrawal from study, whichever came first, assessed up to 24 months.

  6. ORR assessed by investigators (combined criteria incorporating RECIST 1.1 and Gynecological Cancer Intergroup [GCIG]) CA-125 criteria; Ovarian cancer only)

    Defined as the proportion of subjects with confirmed CR or PR before progression as assessed by incorporating both RECIST 1.1 and GCIG CA-125 criteria.

    Time frame: From the first dose to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

  7. CA-125 response rate assessed by investigators according to GCIG CA-125 criteria (ovarian cancer only)

    CA-125 response rate is defined as the proportion of subjects with GCIG CA-125 criteria defined CA-125 response, which will be assessed in a subset of subjects with a baseline CA-125 level of at least twice the ULN as evaluable.

    Time frame: From the first dose to disease progression or withdrawal from study, whichever came first, assessed up to 24 months.

  8. Incidence and severity of adverse events (AEs)

    AEs will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. The incidence and severity of AEs will be calculated and summarized.

    Time frame: From the first dose to 90 days after the end of treatment.

  9. Observed maximum plasma concentration (Cmax) of HS-20089

    Cmax will be obtained following administration of the first dose of HS-20089 during the first cycle.

    Time frame: From pre-dose to 14 days after the first dose of HS-20089 on Cycle 1 (each cycle is 21 days).

  10. Time to reach maximum plasma concentration (Tmax) of HS-20089 following the first dose

    Tmax will be obtained following administration of the first dose of HS-20089 during the first cycle.

    Time frame: From pre-dose to 14 days after the first dose on Cycle 1 (each cycle is 21 days).

  11. Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of HS-20089

    Area under the plasma concentration versus time curve from time zero to the last sampling time when the concentration is no less than the lower limit of quantification (LLQ). AUC0-t will be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: From pre-dose to 14 days after the first dose on Cycle 1 (each cycle is 21 days).

  12. Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) after single dose of HS-20089

    AUC0-∞ will be calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: From pre-dose to 14 days after the first dose on Cycle 1 (each cycle is 21 days).

  13. Percentage of participants with antibodies to HS-20089 in serum

    Serum samples will be collected for the determination of anti-drug antibody (ADA) at designated time points.

    Time frame: From the first dose to 90 days after the end of treatment.

07

Study locations

26 of 28 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 24 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2023
First posted
Aug 28, 2023
StartActual
Dec 18, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2027
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06014190
Responsible party
Sponsor
First posted
Aug 28, 2023
Start date
Dec 18, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 29, 2024

Study contacts

Lingying Wu, MD
Contact
wulingying@csco.org.cn
010-87788996
Dawei Wu
Contact
cancergcp@163.com
010-87788495
Lingying Wu, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mocertatug rezetecan

Start the discussion